← Back to Search
Crizotinib Therapy For Advanced Lung Adenocarcinoma And A ROS1 Rearrangement: Results From The EUROS1 Cohort.
J. Mazieres, G. Zalcman, L. Crinó, P. Biondani, F. Barlési, T. Filleron, A. Dingemans, H. Lena, I. Monnet, S. Rothschild, F. Cappuzzo, B. Besse, L. Thiberville, D. Rouvière, R. Dziadziuszko, E. Smit, J. Wolf, C. Spirig, N. Pécuchet, Frauke Leenders, J. Heuckmann, J. Diebold, J. Milia, R. Thomas, O. Gautschi
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
PURPOSE Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. PATIENTS AND METHODS In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested for ROS1 rearrangement. Eligible patients had stage IV lung adenocarcinoma, had ROS1 rearrangement according to fluorescent in situ hybridization, and had received crizotinib therapy through an individual off-label use. Best response was assessed locally using RECIST (version 1.1). All other data were analyzed centrally. RESULTS We identified 32 eligible patients. One patient was excluded because next-generation sequencing was negative for ROS1 fusion. Median age was 50.5 years, 64.5% of patients were women, and 67.7% were never-smokers. Thirty patients were evaluable for progression-free survival (PFS), and 29 patients were evaluable for best response. We observed four patients with disease progression, two patients with stable disease, and objective response in 24 patients, including five complete responses (overall response rate, 80%; disease control rate, 86.7%). Median PFS was 9.1 months, and the PFS rate at 12 months was 44%. No unexpected adverse effects were observed. Twenty-six patients received pemetrexed (either alone or in combination with platinum and either before or after crizotinib) and had a response rate of 57.7% and a median PFS of 7.2 months. CONCLUSION Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1. Prospective clinical trials with crizotinib and other ROS1 inhibitors are ongoing or planned.
This paper references
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Klarisa Rikova (2007)
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
H. R. Kim (2013)
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
P. Goldstraw (2007)
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
A. Drilon (2013)
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
S. Antoniu (2011)
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Y. Pan (2014)
ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 cases
A. Warth (2014)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
A. Tsao (2012)
plete metabolic response in a patient with repeatedly relapsed non - small
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
L. Sequist (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
P. Jänne (2013)
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
L. Tanoue (2010)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
G. Demetri (2002)
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
O. Gautschi (2013)
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
O. Gautschi (2012)
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
L. Tanoue (2012)
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
S. Ou (2014)
harboring ROS 1 gene rearrangement after treatment with crizotinib
K Dziadziuszko (2013)
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
A. Shaw (2013)
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
D. Camidge (2014)
Mouse Model for ROS1-Rearranged Lung Cancer
Y. Arai (2013)
Characterization of ROS1 cDNA from a human glioblastoma cell line.
C. Birchmeier (1990)
A target or a demi-target.
T. S. Mok (2010)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
M. Christenson (2012)
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
K. Arnaoutakis (2015)
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
H. Yasuda (2012)
Molecular Pathways: ROS1 Fusion Proteins in Cancer
K. Davies (2013)
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
Al Charest (2006)
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
K. Davies (2012)
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
A. Charest (2003)
CD74-NRG1 fusions in lung adenocarcinoma.
L. Fernandez-Cuesta (2014)
Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report.
K. Dziadziuszko (2014)
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm
H. Go (2013)
Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
Carmen Birchmeier (1987)
Acquired Resistance to Crizotinib from a Mutation in CD 74 – ROS 1
Kol Jia Yong (2013)
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
L. Gandhi (2014)
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
L. Mescam-Mancini (2014)
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
M. Gerlinger (2013)
Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
Y. Cha (2014)
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
T. Mok (2014)
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
M. Bos (2013)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H. Joensuu (2001)
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
M. Kim (2014)
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
J. Mazières (2013)
A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
J. Riess (2013)
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
F. Cappuzzo (2006)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
R. Rosell (2012)
New driver mutations in non-small-cell lung cancer.
W. Pao (2011)
RET, ROS1 and ALK fusions in lung cancer
K. Takeuchi (2012)
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.
D. Planchard (2013)
Recent clinical advances in lung cancer management.
D. Johnson (2014)
This paper is referenced by
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines
D. Ettinger (2013)
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
S. E. Jorge (2015)
Oncology in the Precision Medicine Era: Value-Based Medicine
Ravi Salgia (2020)
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
M. Scheffler (2015)
The Incidence of Brain Metastases in Stage IV ROS1‐Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
T. Patil (2018)
Precision drug development in ROS1-positive lung cancer
C. Hardin (2017)
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
Shi-yong Li (2016)
Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature
M. Ambroggi (2018)
Lonely Driver ROS1.
S. Savic (2017)
Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS 1 ‐ positive non ‐ small cell lung cancer
Y. Zhu ()
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1‐Rearranged Non–Small Cell Lung Cancer
Z. Li (2018)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
D. Ettinger (2016)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
D. Ettinger (2018)
Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.
Y. Song (2020)
ROS1 fusions in cancer: a review.
A. Uguen (2016)
Genomic Biomarkers in NSCLC
P. Villalobos (2018)
ROS1 copy number alterations are frequent in non-small cell lung cancer
S. Clavé (2016)
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
A. Drilon (2016)
Mini Review: Challenges and strategies in precision medicine for non-small cell lung cancer
Joseph Sacco (2017)
An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature
Xiao-juan Yang (2019)
ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.
Z. Song (2017)
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
A. Drilon (2015)
Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
L. Cameron (2015)
Capture‐Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA‐Releasing Capability in Advanced Lung Cancer
Xiaowei Mao (2017)
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
C. Su (2017)
Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.
E. Bernicker (2017)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
N. Lindeman (2018)
Prognostic value of site-specific metastases in lung cancer: A population based study
J. Li (2019)
Chapter 2 Genomic aberrations guiding treatment of non-small cell lung cancer patients
Ali Saber (2016)
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Abdulaziz B Hamid (2020)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
R. Roskoski (2017)
A consensus statement on the gender perspective in lung cancer
D. Isla (2016)See more